UK strengthens AI healthcare governance to ensure safety, equity and system-wide evaluation

The Medicines and Healthcare products Regulatory Agency in the UK has outlined priorities for regulating AI in healthcare, focusing on safety, effectiveness and public trust.

An approach that includes strengthening pre-market evaluation and post-market surveillance, particularly for adaptive systems operating in real-world settings.

Contributions from the Health Foundation and the National Commission for the Regulation of AI in Healthcare highlight the need for broader governance frameworks.

These extend beyond technical validation to include implementation challenges, system-wide impacts and the role of human oversight in clinical environments.

The analysis emphasises that AI in healthcare operates as a socio-technical system, requiring assessment of usability, fairness and real-world outcomes. It also identifies gaps in current evaluation practices, particularly in local service assessments, which may lack consistency and reliability.

Strengthening evaluation standards, improving coordination and addressing risks such as bias and inequity are presented as central to enabling safe and scalable adoption.

Such a framework in the UK aims to balance innovation with accountability while ensuring equitable access to healthcare technologies.

Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!